BioSpace News Archive

Use some useful leadership words for resume to sho

Career Advice

Few Outdated Words Not to Use in a Resume

While some classic professional terms and phrases will never go out of style, there are many words not to use in a resume. Look at some of those words here.

May 29, 2018

·

4 min read

Drug Development

Axovant Completes Reorganization, Adds to Management Team

After Axovant Sciences’ spectacular clinical trial failure in September 2017, the company has been reorganizing. Today it announced it had completed that reorganization by adding to its executive team and Scientific Advisory Board.

May 29, 2018

·

3 min read

·

Mark Terry

Drug Development

Two Months After Raising $64 Million, Eidos Therapeutics Announces IPO

On April 5, San Francisco’s Eidos Therapeutics closed on a Series B financing round worth $64 million. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) to raise $115 million through an initial public offering (IPO).

May 29, 2018

·

2 min read

·

Mark Terry

Drug Development

String of Success: Another Genentech Study Shows Tecentriq’s Efficacy in Treating Lung Cancer

A combination of Genentech’s Tecentriq and chemotherapy enabled some lung cancer patients in a Phase III trial to live significantly longer than chemotherapy alone. The latest report continues the string of successes the company has had with Tecentriq, an anti-PD-L1 immunotherapy.

May 29, 2018

·

3 min read

·

Alex Keown

Policy

Trump’s Drug Price Reform Proposal: Toothless or Not?

The biopharma industry has been holding its collective breath all year, wondering what might be coming from the White House.

May 29, 2018

·

3 min read

·

Karl Thiel

Drug Development

Genmab and Johnson & Johnson Halt Lung Cancer Study

Genmab A/S, and Johnson & Johnson’s Janssen division have pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq.

May 29, 2018

·

2 min read

·

Mark Terry

Policy

Former Arcturus CEO Prevails in Lawsuit, Board Members Who Fired Him are Replaced

Shares of Arcturus Therapeutics are up nearly 10 percent this morning after the company announced it reached a settlement with its former chief executive officer and replaced four members of its board of directors with four new ones.

May 29, 2018

·

2 min read

·

Alex Keown

Ublituximab shows better results than Aubagio in p

BioMidwest

On World MS Day Companies Drive Toward a Cure as Patients, Advocates Join Together in Hope

Since 2009 May 30 has been set aside as a day to raise awareness and campaign for an end to multiple sclerosis. The theme this year is focused on the research being conducted to develop a cure for the neurological disease.

May 29, 2018

·

4 min read

·

Alex Keown

Drug Development

FDA Accepts NDAs and Grants Priority Review to Loxo Oncology, Astellas Pharma and Catalyst Pharmaceuticals

Following the long holiday weekend, three pharma companies began the week with good news as the U.S. Food and Drug Administration awarded their therapies with Priority Review Status.

May 29, 2018

·

3 min read

·

Alex Keown

FDA

Pfizer’s Xalkori Snags Breakthrough Therapy Designation for Two New Indications

Pfizer’s Xalkori, the first drug approved in the United States for patients with ALK-positive and ROS1-positive non-small cell lung cancer, secured Breakthrough Therapy Designation from the U.S. Food and Drug Administration for two new indications.

May 29, 2018

·

2 min read

·

Alex Keown